The predictive models and all information available and presented on this webpage were developed for and are intended for research purposes only. The predictive models and all information available on this webpage must under no circumstances be used, wholly or partly, for any clinical decision making and in any other way than for research purposes. The predictive models and all information available and presented on this webpage are intended for use by health care professionals (researchers) only and should under no circumstances be used by any non-health care professional.
If you are a patient or a relative, we strongly advice against using the predictive models and all information available on and presented on this webpage. Instead you should consult your attending physician for prognostic information.
We, the authors of "Simplicity at the cost of predictive accuracy in diffuse large B-cell lymphoma: a critical assessment of the R-IPI, IPI, and NCCN-IPI" and the institutions we represent, are not liable in any form or way for any damages, direct or indirect, arising out of or in connection to the use of the predictive models or any information available on and presented on this webpage.

Patient characteristics

CLL-IPI


The predictive models and all information available and presented on this webpage were developed for and are intended for research purposes only. The predictive models and all information available on this webpage must under no circumstances be used, wholly or partly, for any clinical decision making and in any other way than for research purposes. The predictive models and all information available and presented on this webpage are intended for use by health care professionals (researchers) only and should under no circumstances be used by any non-health care professional.
If you are a patient or a relative, we strongly advice against using the predictive models and all information available on and presented on this webpage. Instead you should consult your attending physician for prognostic information.
We, the authors of "Simplicity at the cost of predictive accuracy in diffuse large B-cell lymphoma: a critical assessment of the R-IPI, IPI, and NCCN-IPI" and the institutions we represent, are not liable in any form or way for any damages, direct or indirect, arising out of or in connection to the use of the predictive models or any information available on and presented on this webpage.

Information

This web-page was developed at the department of Hematology, Aalborg University Hospital. The project was the result of extensive collaboration within the epidemiology working group of the Nordic Lymphoma group. The data was provided by the Danish Lymphoma Register (LYFO) and the Swedish Lymphoma Register (SLR).

Contact

Forskningens Hus (Science and Innovation Center)
Aalborg University Hospital
Department of Haematology
Sdr. Skovvej 15
DK-9000 Aalborg
DENMARK

Telephone: +45 97 66 38 64
Fax: +45 97 66 63 23
E-mail: info@blodet.dk
Website: blodet.dk

Collaborators

Aalborg University Hospital
Jorne Biccler
Lasse Hjort Jakobsen
Martin Bøgsted
Tarec El-Galaly

Karolinska Intistutet
Sandra Eloranta
Karin Ekström Smedby

Lund University
Mats Jerkeman

Rigshopsitalet
Peter de Nully Brown
Michael Asger Andersen

Odense University Hospital
Henrik Frederiksen

References

Diffuse large B-cell lymphoma

Stacking model

Optimizing Outcome Prediction in Diffuse Large B-Cell Lymphoma by use of Machine Learning and Nationwide Lymphoma Registries: a Nordic Lymphoma Group Study

Jorne Biccler, Sandra Eloranta, Peter de Nully Brown, Henrik Frederiksen, Mats Jerkeman, Judit Jørgensen, Hans Erik Johnsen, Lasse Hjort Jakobsen, Karin E. Smedby, Martin Bøgsted, and Tarec C. El-Galaly
Submitted to Clinical Cancer Informatics

Cox proportional hazards model

Simplicity at the cost of predictive accuracy in diffuse large B-cell lymphoma: a critical assessment of the R-IPI, IPI, and NCCN-IPI

Jorne Biccler, Sandra Eloranta, Peter de Nully Brown, Henrik Frederiksen, Mats Jerkeman, Karin E. Smedby, Martin Bøgsted, Tarec C. El-Galaly
Published in Cancer Medicine, Vol. 7, Issue 1

IPI

A Predictive Model for Aggressive Non-Hodgkin's Lymphoma

The International Non-Hodgkin's Lymphoma Prognostic Factors Project
Published in New England Journal of Medicine 1993, Vol. 329, Issue 14

NCCN-IPI

An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era

Zheng Zhou, Laurie H. Sehn, Alfred W. Rademaker, Leo I. Gordon, Ann S. LaCasce, Allison Crosby-Thompson, Ann Vanderplas, Andrew D. Zelenetz, Gregory A. Abel, Maria A. Rodriguez, Auayporn Nademanee, Mark S. Kaminski, Myron S. Czuczman, Michael Millenson, Joyce Niland, Randy D. Gascoyne, Joseph M. Connors, Jonathan W. Friedberg and Jane N. Winter
Published in blood 2014, Vol. 123, Issue 6

R-IPI

The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP

Laurie H. Sehn, Brian Berry, Mukesh Chhanabhai, Catherine Fitzgerald, Karamjit Gill, Paul Hoskins, Richard Klasa, Kerry J. Savage, Tamara Shenkier, Judy Sutherland, Randy D. Gascoyne and Joseph M. Connors
Published in blood 2007, Vol. 109, Issue 5

Chronic lymphocytic leukemia

CLL-IPI

An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data

The International CLL-IPI working group
Published in The Lancet Oncology 2016, Vol. 109, Issue 5